BCL11A and Schnyder corneal dystrophy: Indeed, deactivating BCL11A increases the level of HbF in CD34+ erythroid cell cultures compared to control, and this effect is the basis of the recent gene therapy, exa-cel, for treating hemoglobinopathies such as SCD and β-thalassemia.